NDC codes

FDA NDC Directory
Product NDC (as listed)10019-984Labeler and product segments. Claims need a package NDC.
Product NDC at billing width10019-0984Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
10019-984-01100190984011 BOTTLE in 1 CARTON (10019-984-01) / 100 TABLET in 1 BOTTLE (10019-984-09)Marketed from Aug 7, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Cyclophosphamide
Generic name (nonproprietary)
cyclophosphamide
Active ingredients
Cyclophosphamide — 50 mg/1
Dosage form
Tablet
Route
Oral
Labeler
Baxter Healthcare CorporationNDC labeler code 10019
Product type
Prescription drug
Marketing category
NDA — New Drug ApplicationApplication NDA 012141
Marketing start
Listing expires
Identifiers
Product ID 10019-984_dc40762e-5ccf-402c-a7b1-4c9dee737811SPL ID dc40762e-5ccf-402c-a7b1-4c9dee737811SPL set ID 769ded74-6186-40a8-8e44-ceff67287451RxCUI 197549, 197550UNII 8N3DW7272P

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N410019098401 followed by a unit qualifier and the quantity

Package 10019-0984-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

Cyclophosphamide Tablets is an alkylating drug indicated for treatment of: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 10019-984

What is NDC 10019-984?
10019-984 is the product NDC for Cyclophosphamide, Cyclophosphamide 50 mg/1 tablet, listed with the FDA by Baxter Healthcare Corporation. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Cyclophosphamide.
What is the active ingredient?
Cyclophosphamide.
Who is the labeler?
Baxter Healthcare Corporation, NDC labeler code 10019. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cyclophosphamide?
83 other product NDCs are listed under this name. See all Cyclophosphamide NDCs.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Cyclophosphamide NDCs
ProductStrengthForm · routeLabelerProduct NDCPackage NDCs (11-digit)
CyclophosphamideCyclophosphamide 25 mg/1CapsuleOralOPKO Pharmaceuticals, LLC70301-201370301-2013-01
CyclophosphamideCyclophosphamide 50 mg/1CapsuleOralOPKO Pharmaceuticals, LLC70301-201570301-2015-01
CyclophosphamideCyclophosphamide 200 mg/mLInjectionIntravenousNexus Pharmaceuticals, LLC14789-12514789-0125-05
CyclophosphamideCyclophosphamide 200 mg/mLInjectionIntravenousNexus Pharmaceuticals, LLC14789-12614789-0126-05
CyclophosphamideCyclophosphamide 500 mg/25mLInjection, Powder, For solutionIntravenous, OralBluePoint Laboratories68001-69468001-0694-27
CyclophosphamideCyclophosphamide 1 g/50mLInjection, Powder, For solutionIntravenous, OralBluePoint Laboratories68001-69568001-0695-32
CyclophosphamideCyclophosphamide 2 g/100mLInjection, Powder, For solutionIntravenous, OralBluePoint Laboratories68001-69668001-0696-32
CyclophosphamideCyclophosphamide 500 mg/25mLInjection, Powder, For solutionIntravenous, OralAvenacy, LLC83634-20583634-0205-50
CyclophosphamideCyclophosphamide 1 g/50mLInjection, Powder, For solutionIntravenous, OralAvenacy, LLC83634-20683634-0206-51
CyclophosphamideCyclophosphamide 2 g/100mLInjection, Powder, For solutionIntravenous, OralAvenacy, LLC83634-20783634-0207-51

All 84 Cyclophosphamide NDCs

Other NDCs under NDA 012141

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 012141
ProductStrengthForm · routeLabelerProduct NDC
CyclophosphamideCyclophosphamide 25 mg/1TabletOralBaxter Healthcare Corporation10019-982

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in